Johnson & Johnson (JNJ) reported Q1 FY 2021 earnings of $2.59 per share (versus $2.30 per share in Q1 FY 2020), beating analysts’ consensus estimate of $2.33 per share.

The company’s quarterly revenues amounted to $22.300 bln (+7.8% y/y), beating analysts’ consensus estimate of $21.997 bln.

The company also announced that its Board of Directors declared a 5.0% increase in the quarterly dividend, from $1.01/share to $1.06/share.

In addition, it tightened guidance ranges for FY 2021, projecting EPS of $9.42-$9.57 versus prior guidance of $9.40-$9.60 and analysts’ consensus estimate of $9.52 and revenues of $90.6-$91.6 bln versus prior guidance of $90.5-$91.7 bln and analysts’ consensus estimate of $92.03 bln.

JNJ fell to $162.50 (-0.12%) in pre-market trading.